adenovirus encoding anti-CD20 antibody gene

A recombinant, non-replicative adenovirus engineered to deliver and express the gene encoding an anti-CD20 monoclonal antibody. Upon administration, the **adenoviral vector** infects target host cells, which then produce and secrete anti-CD20 antibody in vivo. The antibody generated by transduced cells exhibits binding affinity and specificity similar to commercial anti-CD20 monoclonal antibodies such as rituximab. This gene therapy approach has been shown in preclinical models (mice and cynomolgus monkeys) to result in high serum concentrations of anti-CD20 antibody and effective depletion of B cells and elimination of B-cell lymphoma cells. Its mechanism relies on antibody-mediated depletion of CD20-positive B cells. Primary indications under study include B-cell lymphomas, autoimmune diseases, and disorders wherein B-cell depletion with anti-CD20 activity is beneficial. This strategy combines aspects of gene therapy and immunotherapy by using the adenovirus as a delivery system to generate therapeutic antibody levels in vivo[1][3].

Other names

adenovirus encoding anti-CD20 antibody generecombinant adenovirus expressing anti-CD20 antibody gene